Beacon provides a scalable EEG analytics platform aimed at accelerating development of therapies in neurology, psychiatry, and sleep medicine. Powered by a combination of FDA-cleared medical devices, unique data assets and machine learning algorithms, our platform captures quantitative EEG endpoints that increase the probability of success at each stage of drug development.
- Sleep Data Acquisition At-Home, and At Scale
- Deploy the Dreem Headband as part of your research and trial efforts in order to collect sleep data and validated sleep endpoints.
- Translational Research
- Analyze existing EEG for insights into mechanism, PK/PD and patient stratification to guide further development efforts.
- Qualified Biomarker Development
- Develop and validate neurobiomarkers to improve cohort selection, de-confound standard clinical assessments, and identify novel endpoints.
- Efficacy & Dose-Finding
- Improve dose-finding with direct neurophysiologic insights and identify promising responses to properly power subsequent trials.
Scalable sleep monitoring for clinical trials. The lightweight, low-profile Dreem 3 device is engineered to optimize EEG signal quality, patient comfort and operational efficiency for obtain longitudinal, PSG-quality data at-home.
A recently published, peer-reviewed study (Arnal et al. 2020) showed that the Dreem headband achieves a level of analysis similar to a PSG for measurement.
Beacon harnesses deep learning and advanced digital signal processing to build algorithms that can predict expert consensus on EEG events more accurately and reliably than any individual expert. This enables high-resolution interrogation of neurophysiological data and construction of novel endpoints that can't be captured by tools like MRI, actigraphy, or genetic analyses.
We go beyond traditional sleep analyses to capture the neural basis of sleep physiology. In addition to algorithmic gold-standard sleep staging from EEG, Beacon’s AI quantifies sleep microarchitecture (e.g. sleep spindles, arousals, etc.) to unlock novel biomarkers for neurodegenerative and psychiatric diseases.
At Beacon, we continuously strive to ensure that our algorithms perform equitably across the diverse patient populations we serve. We believe this is critical to address health care disparities and ensure that novel precision therapies improve brain health for all.
Beacon’s Datastore™ enables extraction of custom cohorts to precisely match a target patient population. Associated metadata supports identification of strata-specific effects and developing mixed models with other clinical data types. Analysis of custom cohorts can drive mechanistic insights, identify novel endpoints and perform power calculations for subsequent trials.
Beacon Datastore™ contains an unparalleled size and diversity of data linked to clinical phenotype, enabling world-class clinical discovery.
Beacon’s Datastore™ includes clinical-grade EEG from thousands of individuals without CNS disease. This normative database accelerates discovery of disease-specific neurobiomarkers and enables identification of drug effects that “normalize” physiologic processes such as sleep architecture.
Our analytic reports summarize subject- and cohort-level results, including clinical EEG interpretation by qualified neurologists and quantitative metrics that would not be possible without automation.
The Portal supports end-to-end clinician workflows that combine in-browser signal processing, interactive data visualization and machine learning reader-assist.
Our network of epileptologists provide central EEG reading services augmented by Beacon’s AI to improve efficiency and ensure standardization. Expert services include safety and toxicity assessments, as well as physician sign-off on clinical trial reports.
We partner with biopharma companies, academic medical centers, and neurotechnology developers to improve the diagnosis and treatment of neurological and psychiatric diseases.